Clinical Trial Update: The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the metabolic effects of empagliflozin in patients with obesity at high risk of heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Obesity

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Jacob Moller | Conditions: Obesity, Heart Failure | Phase 2 | Status: COMPLETED